(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...
Most of us are aware that excess weight around the belly in middle age raises our risk of developing a long list of health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback